| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 162.45 | 1.5% | 21.7% |
| Total Income | 162.63 | 1.5% | 21.1% |
| Expenditure | 146.76 | 1.1% | 10.3% |
| PBT | 15.87 | 4.6% | 1128.0% |
| Net Profit | 15.76 | 3.8% | 1193.8% |
| OPM | 16.43% | 0.32pp | 26.20pp |
| NPM | 9.69% | 0.22pp | 8.78pp |
| EPS | 4.52 | 1.3% | 1089.5% |
Wanbury Ltd Delivers Strong Q3 FY26 Performance with 21.7% Revenue Growth and 1,194.3% PAT Growth
06 Feb 2026 · 6 Feb, 3:24 pm
Summary
Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and nine months ended 31st December 2025. The company reported a Y-o-Y growth of 21.7% in revenue from operations, driven by higher API volumes, improved capacity utilization at key manufacturing facilities and steady performance in the formulations business. The EBITDA stood at 16.5% compared to 11.0% in Q3 FY25, and PAT for the quarter stood at Rs. 15.8 crore, compared to Rs. 1.2 crore in Q3 FY25, registering a significant growth of 1,194.3%.
Key Highlights
- 1
Q3FY26 revenue up 22% YoY; 9MFY26 up 14% YoY, driven by strong demand and higher volumes in API and moderate growth in Formulations segments
- 2
Improved Profitability: Q3FY26 EBITDA surged to 26.9Cr and 9MFY26 EBITDA surged to 77.6Cr improvement of 81.7% YoY in Q3 and 60.6% YoY in 9MFY26 respectively
- 3
PAT Growth: Q3FY26 PAT improved to 15.8Cr from 1.2Cr in Q3FY25 and 9MFY26 PAT increased to 44.4Cr from 10.3Cr in 9MFY25, significant Profit After Tax growth from strong operations and from reduced finance costs
- 4
API Business Highlights: New product launch : Commercial invoicing and shipment to European customer completed for high potent anaesthetic API from cutting edge Tanaku facility is completed in Q3FY26. Further with upcoming new product launches - Antidiabetic, Anticoagulant (Blood thinner), Cough suppressant (Anti Tussive), Antidepressant Wanbury is well positioned for growth in upcoming years
- 5
Formulations Progress: EBITDA positive in Q3 and 9MFY26; witnessed good results from recent launch of nutritional supplement C-Red and other products; healthy pipeline for expansion into new therapeutic categories
Management Comments
Mr. Mohan Rayana
Director of Wanbury Ltd.
Robust Revenue Growth: Q3FY26 revenue up 22% YoY; 9MFY26 up 14% YoY, driven by strong demand and higher volumes in API and moderate growth in Formulations segments. Improved Profitability: Q3FY26 EBITDA surged to 26.9Cr and 9MFY26 EBITDA surged to 77.6Cr improvement of 81.7% YoY in Q3 and 60.6% YoY in 9MFY26 respectively. This was achieved through margin improvements majorly due sales of high margin SKUs, good product mix besides improved productivity due to higher yields, enhanced solvent recovery and improved procurement. PAT Growth: Q3FY26 PAT improved to 15.8Cr from 1.2Cr in Q3FY25 and 9MFY26 PAT increased to 44.4Cr from 10.3Cr in 9MFY25, significant Profit After Tax growth from strong operations and from reduced finance costs.
Informational and educational content only. Not investment advice.